Adjuvant Therapy of HIFU Ablation for Adenomyosis
book-chapter
OA: closed
CC0
Limited metadata. Only one source feed has indexed
this record so far — no abstract, full text, or open-access copy is
available through Endo Lab. The
publisher's page (linked below)
is the canonical location for the actual content. If you have institutional
access, use "Find at my library".
My notes (saved in your browser only)
Condition tags
Citation neighborhood
Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.
References (8)
- Clinical Predictors of Long-term Success in Ultrasound-guided High-intensity Focused Ultrasound Ablation Treatment for Adenomyosis via openalex
- [Clinical study of high intensity focused ultrasound ablation combined with GnRH-a and LNG-IUS for the treatment of adenomyosis]. via openalex
- Combination therapeutic effects of high intensity focused ultrasound and Metformin for the treatment of adenomyosis via openalex
- Combined therapeutic effects of HIFU, GnRH-a and LNG-IUS for the treatment of severe adenomyosis via openalex
- Effect of pre-treatment with gonadotropin-releasing hormone analogue GnRH-α on high-intensity focussed ultrasound ablation for diffuse adenomyosis: a preliminary study via openalex
- High-intensity focused ultrasound (HIFU) combined with gonadotropin-releasing hormone analogs (GnRHa) and levonorgestrel-releasing intrauterine system (LNG-IUS) for adenomyosis: a case series with long-term follow up via openalex
- High intensity focused ultrasound treatment of adenomyosis: a comparative study via openalex
- W2065386825 via openalex
Source provenance
- openalex
- last seen: 2026-06-10T17:14:06.276822+00:00
- unpaywall
- last seen: 2026-06-02T02:00:03.124865+00:00
License: CC0
· commercial use OK